Memic Innovative Surgery
Last updated: May 8, 2026
Memic Innovative Surgery developed a compact surgical robotics platform with miniaturized humanoid arms and high-articulation teleoperation for minimally invasive procedures; the company later rebranded to Momentis Surgical and its technology now sits inside a Medtronic-owned portfolio.
Visit WebsiteCompany Overview
Memic Innovative Surgery was an Or Yehuda, Israel-based surgical robotics company founded in 2013 that built a compact, minimally invasive robot around miniaturized humanoid arms. The system was designed to replicate the surgeon's shoulder, elbow, and wrist-like motion so complex maneuvers could be performed through tight anatomical access points rather than through a large open incision. The current public product identity is Momentis Surgical's Anovo platform, which emphasizes a small footprint, high dexterity, and lower operating-room friction.
The commercial problem this architecture addresses is familiar in robotic surgery: incumbent systems can be effective but are often large, expensive, and optimized for broad abdominal access rather than exceptionally confined workspaces. Memic's design attempted to solve that by combining compact actuation, a two-armed configuration, and highly articulated instruments that could support procedures where reach, triangulation, and access are the binding constraints. That is a real product differentiation, especially in specialties where hospitals want minimally invasive outcomes without the capital burden or workflow complexity associated with the biggest incumbent systems.
From a market perspective, the company sat in the intersection of surgical robotics, women's health, and broader minimally invasive surgery. The public website for Momentis Surgical still markets the same underlying thesis: a small, cost-effective robotic system that can be integrated into the operating room and that preserves direct visual and verbal interaction between the surgeon and the rest of the staff. Memic's rebrand and subsequent acquisition by Medtronic suggest the technology had enough strategic value to be absorbed into a larger medtech platform rather than remain a standalone venture.
For Claw & Talon, the important angle is not only commercial robotics but also the underlying manipulation stack. Compact articulated robots, constrained-space kinematics, and teleoperated precision are all relevant to austere-care environments, forward surgical teams, and eventually some forms of remote or assisted intervention. That said, the defense relevance is indirect rather than weapons-adjacent: the value is in deployable medical capability, not in inherently military functionality, and any fielded use would still require ruggedization, regulatory work, and communications reliability.
Dual-Use Assessment
The core stack has credible dual-use adjacency because compact teleoperated manipulators, extreme dexterity, and small-footprint surgical robots are relevant to both civilian minimally invasive surgery and military or emergency medicine. The defense case is indirect and operational rather than offensive: the platform could support forward surgical care, remote specialist assistance, or constrained-space intervention, but it would still need ruggedization, workflow validation, and communications infrastructure to be usable outside a hospital.
Strategic Fit Assessment
not an independent company for direct diligence as a startup because the business was acquired and the original venture has effectively rolled into a larger medtech platform. The technology itself is strategically validated, but any diligence thesis would need to be pursued through the parent company or adjacent supply-chain and platform opportunities rather than as a standalone venture deal.
Strategic Value to U.S.-Israel Alliance
The platform matters because it demonstrates that surgical robotics can be miniaturized without giving up articulation, which is a useful design pattern for space-constrained medical settings. That capability is strategically relevant to defense medicine, remote-care concepts, and future robot-assisted procedures where footprint, precision, and ergonomics are all first-order constraints.
Key Technologies
- Miniaturized humanoid robotic arms
- Shoulder-elbow-wrist style articulation
- Teleoperated minimally invasive surgery
- Compact operating-room robotics footprint
- High-dexterity manipulation in confined anatomy
- Surgeon-console and instrument control software
Use Cases & Applications
- Minimally invasive gynecologic surgery
- Transvaginal surgical procedures
- Other confined-space minimally invasive operations
- Hospital OR robotics with lower floor-space requirements
- Forward surgical care in austere environments
- Remote specialist-assisted combat casualty surgery
- Compact robotic assistance for mobile medical units
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 8, 2026.
Investor Lens
What this entry is
Acquired asset
Why it may matter
Memic Innovative Surgery may matter as a Robotics & Autonomy entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify technical claims
- Verify regulatory/export-control issues
Main investor questions
- Is this entry a benchmark, buyer, ecosystem node, acquired asset, or strategic reference rather than a live startup opportunity?
- What does this reference clarify about buyers, sector structure, public-market context, or strategic demand?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Memic Innovative Surgery's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What export-control, supply-chain, manufacturing, or classified-market constraints could affect U.S. and allied adoption?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Robotics & Autonomy sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.